All-case post-marketing surveillance (PMS) of pirfenidone in Japan: Clinical characteristics, efficacy and safety profile in >1300 patients with idiopathic pulmonary fibrosis (IPF)
Y. Inoue, A. Azuma, T. Ogura, H. Taniguchi, K. Chida, M. Bando, Y. Niimi, S. Kakutani, M. Suga, Y. Sugiyama, S. Kudoh, T. Nukiwa (Sakai, Tokyo, Yokohama, Seto, Hamamatsu, Shimotsuke, Osaka, Kumamoto, Kiyose, Shibata, Japan)
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Session: Idiopathic pulmonary fibrosis: clinical view
Session type: Poster Discussion
Number: 3369
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Y. Inoue, A. Azuma, T. Ogura, H. Taniguchi, K. Chida, M. Bando, Y. Niimi, S. Kakutani, M. Suga, Y. Sugiyama, S. Kudoh, T. Nukiwa (Sakai, Tokyo, Yokohama, Seto, Hamamatsu, Shimotsuke, Osaka, Kumamoto, Kiyose, Shibata, Japan). All-case post-marketing surveillance (PMS) of pirfenidone in Japan: Clinical characteristics, efficacy and safety profile in >1300 patients with idiopathic pulmonary fibrosis (IPF). Eur Respir J 2013; 42: Suppl. 57, 3369
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: